A Phase 1b Study of Venetoclax in Combination with Pembrolizumab in Subjects with Previously Untreated NSCLC Whose Tumors have High PD-L1 Expression
Brief description of study
This study will evaluate safety of venetoclax in combination with pembrolizumab in subjects with advanced or metastatic NSCLC with high PD-L1 tumor expression. This is the first study evaluating venetoclax in combination with pembrolizumab in advanced or metastatic non-small Cell Lung Cancer (NSCLC) patients with PD-L1 tumor expression. Venetoclax is an investigational drug in this study because it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.
Clinical Study Identifier: s20-00080
ClinicalTrials.gov Identifier: NCT04274907
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
